Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DUT | P33316 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31712151 | 0.96 | GAA (0.67) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL4851745 | 0.91 | RECQL (0.55) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL12767494 | 0.91 | GAA (0.51) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL14057890 | 0.88 | GAA (0.48) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL17641579 | 0.81 | GAA (0.43) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL12903756 | 0.80 | HPGD (0.51) | GAAALDH1A1KMT2AMAPTDUT | |
| SCHEMBL22326350 | 0.80 | GAA (0.88) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL18839622 | 0.79 | GAA (0.39) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL18839769 | 0.79 | GAA (0.39) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL18419336 | 0.78 | DUT (0.47) | GAAALDH1A1KMT2AMAPTDUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640688-A1 | AVERMECTIN DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250074882-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-03-06 | — | — | US | disclosed |
| US-9617261-B2 | Substituted pyridinone compounds as MEK inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-04-11 | — | — | US | disclosed |
| US-9617261-B2 | Substituted pyridinone compounds as MEK inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-04-11 | — | — | US | disclosed |
| US-9617261-B2 | Substituted pyridinone compounds as MEK inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-04-11 | — | — | US | disclosed |
| US-20160108041-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-04-21 | — | — | US | disclosed |
| US-20160108041-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-04-21 | — | — | US | disclosed |
| US-20160108041-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-04-21 | — | — | US | disclosed |
| WO-2014204263-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | THE ASAN FOUNDATION (KR) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014204263-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | THE ASAN FOUNDATION (KR) | 2014-12-24 | — | — | WO | disclosed |
| WO-1993017034-A1 | AMPHOTERICIN B DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108041-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | MAP3K1, MAP3K5, MAP3K6 | GAA 4115/4885ALDH1A1 1460/4885RECQL 1421/4885 |
| US-20250074882-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE | ABL1, JAK1, FGFR1 | GAA 4117/4885ALDH1A1 1448/4885RECQL 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.